Operating with 43 years of industry experience, over 400 licensed products, and 1,750 employees, Sanovel hosted the reception under the motto “Right Place, Right Time in Diabetes” (Diyabette Tam Yeri, Tam Zamanı), highlighting early diagnosis, awareness, and the strategic role of domestic manufacturing in ensuring access to treatment.
Citing International Diabetes Federation (IDF) Diabetes Atlas figures indicating 589 million adults living with diabetes globally—and projections that adult cases in Turkey will exceed 14 million by 2050—the event underscored timely intervention in alignment with this year’s World Diabetes Day theme, “Early Action on Diabetes.”
Hülya Yalın: “We Will Bring GLP-1 Therapies into Our Portfolio”
Stating that Sanovel aims to carry its 20-year heritage in diabetes care forward with innovative therapeutic options, Sanovel CEO Hülya Yalın remarked:
“Throughout our 20-year journey in diabetes, we have focused on addressing diverse therapeutic needs by incorporating preferred molecules into our portfolio in accordance with up-to-date scientific guidelines. Under our motto ‘Right Place, Right Time in Diabetes,’ adopted for World Diabetes Day and our 20th milestone, we highlight the importance of early diagnosis, timely action, and access to the right treatment.
We manufacture leading molecules used in Type 2 diabetes treatment at our production facilities in Turkey. Introducing non-insulin injectable options to patients and adding GLP-1 class therapies to our portfolio in the near future are among our top priorities.”

“Targeting 86 Export Markets for Our Diabetes Medications Within Five Years”
Emphasizing that domestic production is vital for sustainable medicine supply and export competitiveness, Yalın outlined the company’s global roadmap:
“Developing a medicine in Turkey, manufacturing it in Turkey, and delivering it from Turkey to geographies worldwide makes a vital contribution to our country’s pharmaceutical R&D, production, and export strength. Within the next five years, we aim to deliver our diabetes medications to 86 countries and have exports in this therapeutic area account for 38% of our total exports. Our goal is to contribute to the health of more people worldwide with the strength we draw from Turkey.”
Expert Physicians Highlight Treatment Continuity in Session Moderated by Derya Baykal
Sharing her personal journey with diabetes during the reception, Derya Baykal noted that she was diagnosed late, adding: “People living with diabetes carry a baby with them at all times—one whose food and drink require constant attention. In my view, the most essential steps in diabetes are walking even at home, never interrupting treatment, and maintaining consistent monitoring.” Answering Baykal’s questions, specialist physicians emphasized treatment continuity and advised patients to educate themselves sufficiently to actively manage their condition.
Aiming to double its footprint under its Vision 2035 strategy, Sanovel continues to expand its global presence backed by advanced R&D and manufacturing investments.